Literature DB >> 22331365

Metabolic markers and ALT cutoff level for diagnosing nonalcoholic fatty liver disease: a community-based cross-sectional study.

Teruki Miyake1, Teru Kumagi, Masashi Hirooka, Mitsuhito Koizumi, Shinya Furukawa, Teruhisa Ueda, Yoshio Tokumoto, Yoshio Ikeda, Masanori Abe, Kohichiro Kitai, Yoichi Hiasa, Bunzo Matsuura, Morikazu Onji.   

Abstract

BACKGROUND: Untreated nonalcoholic fatty liver disease (NAFLD) may progress to liver cirrhosis or failure and is associated with the development of hepatocellular carcinoma, diabetes, and cardiovascular disease. It is therefore essential to diagnose and treat NAFLD at an early stage. To assist in this effort, this retrospective study explored the risk factors for NAFLD, and derived new surrogates, a revised alanine aminotransferase (ALT) cutoff level and a novel NAFLD index, to identify previously undiagnosed cases of NAFLD.
METHODS: Using a community-based, cross-sectional design, the records of 6,370 Japanese subjects who had undergone at least 1 annual health check-up were reviewed for the identification of subjects meeting the diagnostic criteria for NAFLD and the variables associated with NAFLD for the estimation of ideal ALT cutoff levels.
RESULTS: The results of multivariate analysis of the 1,346 subjects who met the diagnostic criteria for NAFLD confirmed that metabolic disease markers and a novel NAFLD index, using the variables derived from multivariate analysis, were also markers of NAFLD. The ALT cutoff levels for NAFLD diagnosis were estimated at 25 U/L for males and 17 U/L for females.
CONCLUSIONS: ALT level and the novel NAFLD index were confirmed to be surrogate markers for NAFLD in addition to metabolic disease markers. The ALT cutoff level used in NAFLD diagnosis should be revised downward to identify subjects at risk of NAFLD to prevent NAFLD progression and the development of associated diseases.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22331365     DOI: 10.1007/s00535-012-0534-y

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  29 in total

1.  Aspartate aminotransferase and alanine aminotransferase activities in plasma: statistical distributions, individual variations, and reference values.

Authors:  G Siest; F Schiele; M M Galteau; E Panek; J Steinmetz; F Fagnani; R Gueguen
Journal:  Clin Chem       Date:  1975-07       Impact factor: 8.327

2.  Increase in the prevalence of fatty liver in Japan over the past 12 years: analysis of clinical background.

Authors:  Sei-Ichiro Kojima; Norihito Watanabe; Makoto Numata; Tetsuhei Ogawa; Shohei Matsuzaki
Journal:  J Gastroenterol       Date:  2003       Impact factor: 7.527

3.  Ultrasonographical diagnosis of fatty liver: significance of the liver-kidney contrast.

Authors:  Y Yajima; K Ohta; T Narui; R Abe; H Suzuki; M Ohtsuki
Journal:  Tohoku J Exp Med       Date:  1983-01       Impact factor: 1.848

4.  Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome.

Authors:  Giulio Marchesini; Elisabetta Bugianesi; Gabriele Forlani; Fernanda Cerrelli; Marco Lenzi; Rita Manini; Stefania Natale; Ester Vanni; Nicola Villanova; Nazario Melchionda; Mario Rizzetto
Journal:  Hepatology       Date:  2003-04       Impact factor: 17.425

5.  Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study.

Authors:  Giorgio Bedogni; Lucia Miglioli; Flora Masutti; Claudio Tiribelli; Giulio Marchesini; Stefano Bellentani
Journal:  Hepatology       Date:  2005-07       Impact factor: 17.425

Review 6.  Diabetes and liver disease: an ominous association.

Authors:  Simona Moscatiello; Rita Manini; Giulio Marchesini
Journal:  Nutr Metab Cardiovasc Dis       Date:  2007-01       Impact factor: 4.222

7.  Nonalcoholic steatohepatitis: cirrhosis, hepatocellular carcinoma, and burnt-out NASH.

Authors:  Yoko Yoshioka; Etsuko Hashimoto; Satoru Yatsuji; Hiroyuki Kaneda; Makiko Taniai; Katsutoshi Tokushige; Keiko Shiratori
Journal:  J Gastroenterol       Date:  2004-12       Impact factor: 7.527

8.  Imaging of nonalcoholic steatohepatitis: advantages and pitfalls of ultrasonography and computed tomography.

Authors:  Maki Tobari; Etsuko Hashimoto; Satoru Yatsuji; Nobuyuki Torii; Keiko Shiratori
Journal:  Intern Med       Date:  2009-05-15       Impact factor: 1.271

9.  The severity of nonalcoholic fatty liver disease is associated with increased cardiovascular risk in a large cohort of non-obese Asian subjects.

Authors:  Ki Chul Sung; Marno C Ryan; Andrew M Wilson
Journal:  Atherosclerosis       Date:  2008-07-31       Impact factor: 5.162

10.  Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study.

Authors:  Hyeon Chang Kim; Chung Mo Nam; Sun Ha Jee; Kwang Hyub Han; Dae Kyu Oh; Il Suh
Journal:  BMJ       Date:  2004-03-17
View more
  21 in total

1.  Exposure to disinfection byproducts and risk of type 2 diabetes: a nested case-control study in the HUNT and Lifelines cohorts.

Authors:  Stephanie Gängler; Melanie Waldenberger; Anna Artati; Jerzy Adamski; Jurjen N van Bolhuis; Elin Pettersen Sørgjerd; Jana van Vliet-Ostaptchouk; Konstantinos C Makris
Journal:  Metabolomics       Date:  2019-04-08       Impact factor: 4.290

2.  Correlation of serum alanine aminotransferase and aspartate aminotransferase with coronary heart disease.

Authors:  Jianying Shen; Jingying Zhang; Jing Wen; Qiang Ming; Ji Zhang; Yawei Xu
Journal:  Int J Clin Exp Med       Date:  2015-03-15

3.  Reply to the letter by Lai et al. regarding "body mass index is the most useful predictive factor for the onset of nonalcoholic fatty liver disease: a community-based retrospective longitudinal study".

Authors:  Teruki Miyake; Teru Kumagi; Shinya Furukawa; Masanori Abe; Yoichi Hiasa; Bunzo Matsuura; Morikazu Onji
Journal:  J Gastroenterol       Date:  2013-01-30       Impact factor: 7.527

4.  Short sleep duration reduces the risk of nonalcoholic fatty liver disease onset in men: a community-based longitudinal cohort study.

Authors:  Teruki Miyake; Teru Kumagi; Shinya Furukawa; Masashi Hirooka; Keitarou Kawasaki; Mitsuhito Koizumi; Yasuhiko Todo; Shin Yamamoto; Yoshio Tokumoto; Yoshio Ikeda; Masanori Abe; Kohichiro Kitai; Bunzo Matsuura; Yoichi Hiasa
Journal:  J Gastroenterol       Date:  2014-08-13       Impact factor: 7.527

5.  Body mass index is the most useful predictive factor for the onset of nonalcoholic fatty liver disease: a community-based retrospective longitudinal cohort study.

Authors:  Teruki Miyake; Teru Kumagi; Masashi Hirooka; Shinya Furukawa; Mitsuhito Koizumi; Yoshio Tokumoto; Teruhisa Ueda; Shin Yamamoto; Masanori Abe; Kohichiro Kitai; Yoichi Hiasa; Bunzo Matsuura; Morikazu Onji
Journal:  J Gastroenterol       Date:  2012-08-31       Impact factor: 7.527

6.  Differences in the risk of fatty liver for onset of impaired fasting glucose according to baseline plasma glucose levels.

Authors:  Teruki Miyake; Masashi Hirooka; Osamu Yoshida; Shinya Furukawa; Teru Kumagi; Mitsuhito Koizumi; Shin Yamamoto; Taira Kuroda; Eiji Arimitsu; Eiji Takeshita; Masanori Abe; Kohichiro Kitai; Bunzo Matsuura; Yoichi Hiasa
Journal:  J Gastroenterol       Date:  2016-06-24       Impact factor: 7.527

7.  Significance of exercise in nonalcoholic fatty liver disease in men: a community-based large cross-sectional study.

Authors:  Teruki Miyake; Teru Kumagi; Masashi Hirooka; Shinya Furukawa; Keitarou Kawasaki; Mitsuhito Koizumi; Yasuhiko Todo; Shin Yamamoto; Hiroaki Nunoi; Yoshio Tokumoto; Yoshio Ikeda; Masanori Abe; Kohichiro Kitai; Bunzo Matsuura; Yoichi Hiasa
Journal:  J Gastroenterol       Date:  2014-04-21       Impact factor: 7.527

8.  Hyperuricemia is a risk factor for the onset of impaired fasting glucose in men with a high plasma glucose level: a community-based study.

Authors:  Teruki Miyake; Teru Kumagi; Shinya Furukawa; Masashi Hirooka; Keitarou Kawasaki; Mitsuhito Koizumi; Yasuhiko Todo; Shin Yamamoto; Masanori Abe; Kohichiro Kitai; Bunzo Matsuura; Yoichi Hiasa
Journal:  PLoS One       Date:  2014-09-19       Impact factor: 3.240

9.  Retrospective study of factors associated with progression and remission/regression of diabetic kidney disease-hypomagnesemia was associated with progression and elevated serum alanine aminotransferase levels were associated with remission or regression.

Authors:  Tatsuo Yanagawa; Keiko Koyano; Koichiro Azuma
Journal:  Diabetol Int       Date:  2021-01-02

10.  NADH dehydrogenase subunit-2 237 Leu/Met polymorphism modifies effects of cigarette smoking on risk of elevated levels of serum liver enzyme in male Japanese health check-up examinees: a cross-sectional study.

Authors:  Akatsuki Kokaze; Masao Yoshida; Mamoru Ishikawa; Naomi Matsunaga; Kanae Karita; Tadahiro Ohtsu; Hirotaka Ochiai; Takako Shirasawa; Hinako Nanri; Yuta Baba; Hiromi Hoshino; Yutaka Takashima
Journal:  Tob Induc Dis       Date:  2014-07-10       Impact factor: 2.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.